Miscellaneous Central Nervous System Intoxicants

Critical Care Clinics

Volumn 28, Issue 4, 2012, Pages 587-600

  Hedge, Matthew W ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Central nervous system; Intoxicants; Overdose; Therapeutic drugs

Indexed keywords

ACTIVATED CARBON; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CARBAMAZEPINE; CARNITINE; CITALOPRAM; CLOZAPINE; DULOXETINE; ELECTROLYTE; ESCITALOPRAM; GLUCOSE; LIPID EMULSION; OLANZAPINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PROPOFOL; QUETIAPINE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRIPLE REUPTAKE INHIBITOR; VALPROIC ACID; VENLAFAXINE; VOLTAGE GATED SODIUM CHANNEL;

ANXIETY DISORDER; ASSISTED VENTILATION; ATAXIA; BIPOLAR DISORDER; BLOOD CLOTTING DISORDER; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DEPRESSION; CONFUSION; DELIRIUM; DEPRESSION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAPHY; ELECTROLYTE BLOOD LEVEL; FIBROMYALGIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTHERMIA; INCIDENCE; INTESTINE LAVAGE; KIDNEY INJURY; MIGRAINE; MYDRIASIS; NERVE CELL; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPATHIC PAIN; NEUROTOXICITY; NEUROTRANSMISSION; PRIORITY JOURNAL; QRS COMPLEX; REVIEW; RHABDOMYOLYSIS; SEIZURE; SUPPLEMENTATION; TACHYCARDIA; URINE RETENTION; XEROSTOMIA;

AIRWAY MANAGEMENT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; DRUG OVERDOSE; HUMANS; SEIZURES;

EID: 84866484557     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2012.07.009     Document Type: Review

References (103)

1. Foley K.F., DeSanty K.P., Kast R.E. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother 2006, 6(9):1249-1265.
2. Montgomery S.A. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr 2008, 13(7 Suppl 11):27-33.
3. Khalifa M., Daleau P., Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999, 291(1):280-284.
4. Ayers S., Tobias J.D. Bupropion overdose in an adolescent. Pediatr Emerg Care 2001, 17(2):104-106.
5. Waring W.S., Gray J.A., Graham A. Predictive factors for generalized seizures after deliberate citalopram overdose. Br J Clin Pharmacol 2008, 66(6):861-865.
6. Lobello K.W., Preskorn S.H., Guico-Pabia J., et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 2010, 71(11):1482-1487.
7. Stahl S.M., Grady M.M., Moret C., et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005, 10(9):732-747.
8. Fantaskey A., Burkhart K.K. A case report of venlafaxine toxicity. J Toxicol Clin Toxicol 1995, 33(4):359-361.
9. Chan A.N., Gunja N., Ryan C.J. A comparison of venlafaxine and SSRIs in deliberate self-poisoning. J Med Toxicol 2010, 6(2):116-121.
10. White C.M., Gailey R.A., Levin G.M., et al. Seizure resulting from a venlafaxine overdose. Ann Pharmacother 1997, 31(2):178-180.
11. Thundiyil J.G., Kearney T.E., Olson K.R. Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System. J Med Toxicol 2007, 3(1):15-19.
12. Isbister G.K. Electrocardiogram changes and arrhythmias in venlafaxine overdose. Br J Clin Pharmacol 2009, 67(5):572-576.
13. Glassman A.H., Preud'homme X.A. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993, 54(Suppl):16-22.
14. Kumar V.V., Isbister G.K., Duffull S.B. The effect of decontamination procedures on the pharmacodynamics of venlafaxine in overdose. Br J Clin Pharmacol 2011, 72(1):125-132.
15. Djogovic D., Hudson D., Jacka M. Gastric bezoar following venlafaxine overdose. Clin Toxicol (Phila) 2007, 45(6):735.
16. Bosse G.M., Spiller H.A., Collins A.M. A fatal case of venlafaxine overdose. J Med Toxicol 2008, 4(1):18-20.
17. Hillyard S.G., Barrera-Groba C., Tighe R. Intralipid reverses coma associated with zopiclone and venlafaxine overdose. Eur J Anaesthesiol 2010, 27(6):582-583.
18. Howell C., Wilson A.D., Waring W.S. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 2007, 64(2):192-197.
19. Sharma A.N., Hoffman R.J. Toxin-related seizures. Emerg Med Clin North Am 2011, 29(1):125-139.
20. Wills B., Erickson T. Chemically induced seizures. Clin Lab Med 2006, 26(1):185-209. ix.
21. Belson M.G., Kelley T.R. Bupropion exposures: clinical manifestations and medical outcome. J Emerg Med 2002, 23(3):223-230.
22. Balit C.R., Lynch C.N., Isbister G.K. Bupropion poisoning: a case series. Med J Aust 2003, 178(2):61-63.
23. Boora K., Cummings M.R., Marshall D.R. Generalized seizure in three adolescents with bupropion overdose. J Child Adolesc Psychopharmacol 2010, 20(2):159-160.
24. Harris C.R., Gualtieri J., Stark G. Fatal bupropion overdose. J Toxicol Clin Toxicol 1997, 35(3):321-324.
25. Donnelly K., Walkowiak H.B., Donnelly C., et al. Bupropion toxicokinetic: a case report. Clin Toxicol (Phila) 2010, 48(4):385-387.
26. Jepsen F., Matthews J., Andrews F.J. Sustained release bupropion overdose: an important cause of prolonged symptoms after an overdose. Emerg Med J 2003, 20(6):560-561.
27. Isbister G.K., Balit C.R. Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother 2003, 37(7-8):999-1002.
28. Jackson W.K., Roose S.P., Glassman A.H. Cardiovascular toxicity of antidepressant medications. Psychopathology 1987, 20(Suppl 1):64-74.
29. Weinberg G.L., VadeBoncouer T., Ramaraju G.A., et al. Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats. Anesthesiology 1998, 88(4):1071-1075.
30. Mirtallo J.M., Dasta J.F., Kleinschmidt K.C., et al. State of the art review: intravenous fat emulsions: current applications, safety profile, and clinical implications. Ann Pharmacother 2010, 44(4):688-700.
31. Cave G., Harvey M. Intravenous lipid emulsion as antidote beyond local anesthetic toxicity: a systematic review. Acad Emerg Med 2009, 16(9):815-824.
32. Kolecki P. Isolated venlafaxine-induced serotonin syndrome. J Emerg Med 1997, 15(4):491-493.
33. Boyer E.W., Shannon M. The serotonin syndrome. N Engl J Med 2005, 352(11):1112-1120.
34. Flanagan R.J. Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008, 23(Suppl 1):43-51.
35. Rajapakse S., Abeynaike L., Wickramarathne T. Venlafaxine-associated serotonin syndrome causing severe rhabdomyolysis and acute renal failure in a patient with idiopathic Parkinson disease. J Clin Psychopharmacol 2010, 30(5):620-622.
36. Graudins A., Stearman A., Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998, 16(4):615-619.
37. Bever K.A., Perry P.J. Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy. Am J Health Syst Pharm 1998, 55(10):1003-1016.
38. Steinberg M., Morin A.K. Mild serotonin syndrome associated with concurrent linezolid and fluoxetine. Am J Health Syst Pharm 2007, 64(1):59-62.
39. Gillman P.K. Serotonin syndrome treated with chlorpromazine. J Clin Psychopharmacol 1997, 17(2):128-129.
40. Nisijima K., Yoshino T., Ishiguro T. Risperidone counteracts lethality in an animal model of the serotonin syndrome. Psychopharmacology (Berl) 2000, 150(1):9-14.
41. Meltzer H.Y., Massey B.W. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011, 11(1):59-67.
42. Centorrino F., Price B.H., Tuttle M., et al. EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiatry 2002, 159(1):109-115.
43. Yokota K., Tatebayashi H., Matsuo T., et al. The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics. Br J Pharmacol 2002, 135(6):1547-1555.
44. Amann B.L., Pogarell O., Mergl R., et al. EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects. Hum Psychopharmacol 2003, 18(8):641-646.
45. Tan H.H., Hoppe J., Heard K. A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. Am J Emerg Med 2009, 27(5):607-616.
46. Oulis P., Florakis A., Markatou M., et al. Corrected QT interval changes during electroconvulsive therapy-antidepressants-atypical antipsychotics coadministration: safety issues. J ECT 2011, 27(1):e4-e6.
47. Eyer F., Pfab R., Felgenhauer N., et al. Clinical and analytical features of severe suicidal quetiapine overdoses-a retrospective cohort study. Clin Toxicol (Phila) 2011, 49(9):846-853.
48. McCabe J.L., Menegazzi J.J., Cobaugh D.J., et al. Recovery from severe cyclic antidepressant overdose with hypertonic saline/dextran in a swine model. Acad Emerg Med 1994, 1(2):111-115.
49. Caroff S.N., Mann S.C. Neuroleptic malignant syndrome and malignant hyperthermia. Anaesth Intensive Care 1993, 21(4):477-478.
50. Gillman P.K. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov Disord 2010, 25(12):1780-1790.
51. Baguley I.J. The excitatory: inhibitory ratio model (EIR model): an integrative explanation of acute autonomic overactivity syndromes. Med Hypotheses 2008, 70(1):26-35.
52. Gurrera R.J., Caroff S.N., Cohen A., et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 2011, 72(9):1222-1228.
53. Boutaud O., Roberts L.J. Mechanism-based therapeutic approaches to rhabdomyolysis-induced renal failure. Free Radic Biol Med 2011, 51(5):1062-1067.
54. Stoner S.C., Berry A. Suspected neuroleptic malignant syndrome during quetiapine-clozapine cross-titration. J Pharm Pract 2010, 23(1):69-73.
55. Tsai M.C., Huang T.L. Severe neuroleptic malignant syndrome: successful treatment with high-dose lorazepam and diazepam: a case report. Chang Gung Med J 2010, 33(5):576-580.
56. Gortney J.S., Fagan A., Kissack J.C. Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother 2009, 43(4):785-791.
57. van Maldegem B.T., Smit L.M., Touw D.J., et al. Neuroleptic malignant syndrome in a 4-year-old girl associated with alimemazine. Eur J Pediatr 2002, 161(5):259-261.
58. Tural U., Onder E. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci 2010, 64(1):79-87.
59. Potter J.M., Donnelly A. Carbamazepine-10,11-epoxide in therapeutic drug monitoring. Ther Drug Monit 1998, 20(6):652-657.
60. Tutor-Crespo M.J., Hermida J., Tutor J.C. Relative proportions of serum carbamazepine and its pharmacologically active 10,11-epoxy derivative: effect of polytherapy and renal insufficiency. Ups J Med Sci 2008, 113(2):171-180.
61. Ciszowski K., Szpak D., Jenner B. The influence of carbamazepine plasma level on blood pressure and some ECG parameters in patients with acute intoxication. Przegl Lek 2007, 64(4-5):248-251.
62. Sano R., Takahashi K., Kominato Y., et al. A case of fatal drug intoxication showing a high-density duodenal content by postmortem computed tomography. Leg Med (Tokyo) 2011, 13(1):39-40.
63. Tenenbein M. Position statement: whole bowel irrigation. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1997, 35(7):753-762.
64. Graudins A., Peden G., Dowsett R.P. Massive overdose with controlled-release carbamazepine resulting in delayed peak serum concentrations and life-threatening toxicity. Emerg Med (Fremantle) 2002, 14(1):89-94.
65. Sullivan J.B., Rumack B.H., Peterson R.G. Acute carbamazepine toxicity resulting from overdose. Neurology 1981, 31(5):621-624.
66. Baptiste S.L., Tang H.M., Kuzniecky R.I., et al. Comparison of the antiepileptic properties of transmeningeally delivered muscimol, lidocaine, midazolam, pentobarbital and GABA, in rats. Neurosci Lett 2010, 469(3):421-424.
67. Myhrer T., Enger S., Aas P. Pharmacological therapies against soman-induced seizures in rats 30 min following onset and anticonvulsant impact. Eur J Pharmacol 2006, 548(1-3):83-89.
68. A modulators microinfused into area tempestas or substantia nigra in rats exposed to soman. Arch Toxicol 2006, 80(8):502-507.
69. Vale J.A., Krenzelok E.P., Barceloux G.D. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1999, 37(6):731-751.
70. Pilapil M., Petersen J. Efficacy of hemodialysis and charcoal hemoperfusion in carbamazepine overdose. Clin Toxicol (Phila) 2008, 46(4):342-343.
71. Bek K., Doçak Ş., özkaya, et al. Carbamazepine poisoning managed with haemodialysis and haemoperfusion in three adolescents. Nephrology (Carlton) 2007, 12(1):33-35.
72. Hariton C., Ciesielski L., Simler S., et al. Distribution of sodium valproate and GABA metabolism in CNS of the rat. Biopharm Drug Dispos 1984, 5(4):409-414.
73. Johannessen C.U. Mechanisms of action of valproate: a commentatory. Neurochem Int 2000, 37(2-3):103-110.
74. Katiyar A., Aaron C. Case files of the Children's Hospital of Michigan Regional Poison Control Center: the use of carnitine for the management of acute valproic acid toxicity. J Med Toxicol 2007, 3(3):129-138.
75. Lee W.L., Yang C.C., Deng J.F., et al. A case of severe hyperammonemia and unconsciousness following sodium valproate intoxication. Vet Hum Toxicol 1998, 40(6):346-348.
76. Thanacoody R.H. Extracorporeal elimination in acute valproic acid poisoning. Clin Toxicol (Phila) 2009, 47(7):609-616.
77. Robinson P., Abbott C. Severe hypothermia in association with sodium valproate overdose. N Z Med J 2005, 118(1223):U1681.
78. Houghton B.L., Bowers J.B. Valproic acid overdose: a case report and review of therapy. MedGenMed 2003, 5(1):1. Available at:, Accessed January 23, 2012. http://www.medscape.com/viewarticle/445062.
79. Jung J., Eo E., Ahn K.O. A case of hemoperfusion and L-carnitine management in valproic acid overdose. Am J Emerg Med 2008, 26(3):388.e3-388.e4.
80. Khoo S.H., Leyland M.J. Cerebral edema following acute sodium valproate overdose. J Toxicol Clin Toxicol 1992, 30(2):209-214.
81. Ishikura H., Matsuo N., Matsubara M., et al. Valproic acid overdose and L-carnitine therapy. J Anal Toxicol 1996, 20(1):55-58.
82. Tein I. Carnitine transport: pathophysiology and metabolism of known molecular defects. J Inherit Metab Dis 2003, 26(2-3):147-169.
83. Oechsner M., Steen C., Stürenburg H.J., et al. Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency. J Neurol Neurosurg Psychiatr 1998, 64(5):680-682.
84. Eyer F., Felgenhauer N., Gempel K., et al. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J Clin Psychopharmacol 2005, 25(4):376-380.
85. Espinoza O., Maradei I., Ramírez M., et al. An unusual presentation of opioid-like syndrome in pediatric valproic acid poisoning. Vet Hum Toxicol 2001, 43(3):178-179.
86. Montero F.J. Naloxone in the reversal of coma induced by sodium valproate. Ann Emerg Med 1999, 33(3):357-358.
87. Roberge R.J., Francis E.H. Use of naloxone in valproic acid overdose: case report and review. J Emerg Med 2002, 22(1):67-70.
88. Graudins A., Aaron C.K. Delayed peak serum valproic acid in massive divalproex overdose-treatment with charcoal hemoperfusion. J Toxicol Clin Toxicol 1996, 34(3):335-341.
89. Ingels M., Beauchamp J., Clark R.F., et al. Delayed valproic acid toxicity: a retrospective case series. Ann Emerg Med 2002, 39(6):616-621.
90. van den Broek M.P., Sikma M.A., Ververs T.F., et al. Severe valproic acid intoxication: case study on the unbound fraction and the applicability of extracorporeal elimination. Eur J Emerg Med 2009, 16(6):330-332.
91. Vannaprasaht S., Tiamkao S., Sirivongs D., et al. Acute valproic acid overdose: enhance elimination with multiple-doses activated charcoal. J Med Assoc Thai 2009, 92(8):1113-1115.
92. Franssen E.J., van Essen G.G., Portman A.T., et al. Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. Ther Drug Monit 1999, 21(3):289-292.
93. Matsumoto J., Ogawa H., Ameyama R., et al. Successful treatment by direct hemoperfusion of coma possibly resulting from mitochondrial dysfunction in acute valproate intoxication. Epilepsia 1997, 38(8):950-953.
94. Engbersen R., Kramers C. Enhanced extracorporeal elimination of valproic acid in overdose. Neth J Med 2004, 62(9):307-308.
95. Kane S.L., Constantiner M., Staubus A.E., et al. High-flux hemodialysis without hemoperfusion is effective in acute valproic acid overdose. Ann Pharmacother 2000, 34(10):1146-1151.
96. Johnson L.Z., Martinez I., Fernández M.C., et al. Successful treatment of valproic acid overdose with hemodialysis. Am J Kidney Dis 1999, 33(4):786-789.
97. Meek M.F., Broekroelofs J., Yska J.P., et al. Valproic acid intoxication: sense and non-sense of haemodialysis. Neth J Med 2004, 62(9):333-336.
98. Singh S.M., McMormick B.B., Mustata S., et al. Extracorporeal management of valproic acid overdose: a large regional experience. J Nephrol 2004, 17(1):43-49.
99. Dichtwald S., Dahan E., Adi N., et al. Molecular adsorbent recycling system therapy in the treatment of acute valproic acid intoxication. Isr Med Assoc J 2010, 12(5):307-308.
100. Lheureux P.E., Penaloza A., Zahir S., et al. Science review: carnitine in the treatment of valproic acid-induced toxicity-what is the evidence?. Crit Care 2005, 9(5):431-440.
101. Lheureux P.E., Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009, 47(2):101-111.
102. Perrott J., Murphy N.G., Zed P.J. L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann Pharmacother 2010, 44(7-8):1287-1293.
103. Licari E., Calzavacca P., Warrillow S.J., et al. Life-threatening sodium valproate overdose: a comparison of two approaches to treatment. Crit Care Med 2009, 37(12):3161-3164.